Reviva Pharmaceuticals Holdings (RVPH) Income from Continuing Operations (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Income from Continuing Operations of 3195987.0 for Q1 2026, up 7.06% sequentially from 3438644.0 in Q4 2025, and up 50.32% YoY from 2126155.71 in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Income from Continuing Operations for 9 years, with the latest figure at 3195987.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 50.32% year-over-year to 3195987.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16699014.0 (down 1895.73% YoY) and the FY2025 annual result came in at 19935867.0, down 28041.71% from the prior year.
- Income from Continuing Operations grew to 3195987.0 in Q1 2026 per RVPH's latest filing, from 3438644.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 23588484.0 in Q4 2024 and troughed at 12024069.0 in Q4 2022.
- A 5-year average of 5332816.0 and a median of 6851689.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 675.84% in 2022, then jumped 353.52% in 2024.
- Over 5 years, Income from Continuing Operations stood at 12024069.0 in 2022, then rose by 22.62% to 9304515.0 in 2023, then surged by 353.52% to 23588484.0 in 2024, then plunged by 114.58% to 3438644.0 in 2025, then gained by 7.06% to 3195987.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 3195987.0, 3438644.0, and 4010773.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | -2.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.45 Mn |
| Mar 31, 2026 | -3.20 Mn |
| Dec 31, 2025 | -3.44 Mn |
| Sep 30, 2025 | -4.01 Mn |
| Jun 30, 2025 | -6.05 Mn |
| Mar 31, 2025 | -6.43 Mn |
| Dec 31, 2024 | 23.59 Mn |
| Sep 30, 2024 | -8.37 Mn |
| Jun 30, 2024 | -7.86 Mn |
| Mar 31, 2024 | -7.43 Mn |
| Dec 31, 2023 | -9.30 Mn |
| Sep 30, 2023 | -11.35 Mn |
| Jun 30, 2023 | -11.71 Mn |
| Mar 31, 2023 | -6.85 Mn |
| Dec 31, 2022 | -12.02 Mn |
| Sep 30, 2022 | -3.52 Mn |
| Jun 30, 2022 | -5.34 Mn |
| Mar 31, 2022 | -7.37 Mn |
| Dec 13, 2021 | -3.68 Mn |
| Sep 30, 2021 | -2.28 Mn |